Home / Resources / Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries

Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries

ホワイトペーパー
薬事規制関連支援サービス
Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries_hero image

The European Medicines Agency (EMA) and the US Food and Drug Administration differ on their approach to plain language summaries (PLS) of clinical trials.

Related products
Patients reading trial results summaries
臨床試験結果の要約
このユーザーフレンドリーなポータルは、スポンサー間で臨床試験結果の概要を集約します
Automated submissions to Clinical Trials
TrialScope Disclose
臨床試験情報開示の管理において最も広く信頼されているソリューション
Using Trialscope Intelligence to reduce manual work
TrialScope Intelligence
グローバルな臨床試験情報開示のコンプライアンスに必要な重要な規制知識の集中化された対話型のリポジトリ

Related resources

Trial Summaries-Improving Patient-Centric Communications resource-card-thumbnail
JUL 01, 2023
ホワイトペーパー
薬事規制関連支援サービス

Trial Summaries Improving Patient-Centric Communications

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022

Hands typing on a laptop device.
DEC 17, 2021
ニュース記事
薬事規制関連支援サービス

Considerations for Creating Plain Language Summaries

Writing plain language summaries can be a huge undertaking, especially if translations or a patient review panel are required. See what PLS should include.

View all resources